NCT03219892

Brief Summary

This study is a double blind comparative study examining the effectiveness of the rTMS treatment on Freezing of Gait (FOG) in patients with Parkinson's disease (PD). The investigators hypothesize that treatment with rTMS on supplemental motor area will improve gait quality and decrease the frequency of FOG in PD patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2016

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

July 3, 2017

Completed
15 days until next milestone

First Posted

Study publicly available on registry

July 18, 2017

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
1.5 years until next milestone

Results Posted

Study results publicly available

May 14, 2021

Completed
Last Updated

May 14, 2021

Status Verified

April 1, 2021

Enrollment Period

3 years

First QC Date

July 3, 2017

Results QC Date

June 28, 2020

Last Update Submit

April 22, 2021

Conditions

Keywords

freezing of gaitrTMSfMRI

Outcome Measures

Primary Outcomes (1)

  • Changes of the New Freezing of Gait Questionnaire (NFOGQ) Score

    NFOGQ ranges from 0-24 points. It is used to quantify changes of the FOG frequency and severity. Higher scores mean a worse outcome.

    Pre-treatment, post-treatment 4 weeks

Secondary Outcomes (4)

  • Motor Subscale of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS Part III)

    Pre-treatment, post-treatment 4 weeks

  • Cadence

    Pre-treatment, post-treatment 4 weeks

  • Turning Duration

    Pre-treatment, post-treatment 4 weeks

  • Changes of Brain Functional Connectivity.

    Pre-treatment, post-treatment at 2 weeks

Study Arms (2)

High-frequency rTMS

EXPERIMENTAL

Patients randomized to this group will receive rTMS delivering over the supplementary motor area (SMA). Each treatment consists 1000 pulses (5-second burst of 10Hz rTMS, repeated 20 times at every minute ).Stimulus intensity is 90% of resting motor threshold. A figure-of-8 coil is connected to a biphasic magnetic stimulator, and the induced current is perpendicular to the midline.

Device: High-frequency rTMS

Sham rTMS

SHAM COMPARATOR

Patients randomized to this group will receive the sham rTMS. The procedure is same as used in patients receiving experimental rTMS, except that the coil is angled 90° away.

Device: Sham rTMS

Interventions

It is delivered at a 5-second burst of 10Hz stimuli, repeated 20 times at every minute. Each treatment contains a total of 1000 pulses. Stimulus intensity is 90% of resting motor threshold. The SMA stimulation will be given using a coil centered at points 3-cm anterior to the leg motor area in the sagittal midline.

High-frequency rTMS
Sham rTMSDEVICE

The procedure will be same as the high-frequency rTMS except that the coil is 90° angled away.

Sham rTMS

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Idiopathic PD patients.
  • Presenting with FOG.
  • The mini-mental state examination questionnaire score above 24 points.

You may not qualify if:

  • Other neurological or psychiatric disorders.
  • History of epilepsy, seizures or convulsions.
  • Metal implantation.
  • History of exposure to rTMS in the past (to minimizing risk of unblinding sham condition).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xuanwu Hospital

Beijing, 100053, China

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Results Point of Contact

Title
Piu Chan
Organization
Xuanwu Hospital

Study Officials

  • Piu Chan, MD, PhD

    Xuanwu Hospital, Beijing

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

July 3, 2017

First Posted

July 18, 2017

Study Start

December 1, 2016

Primary Completion

December 1, 2019

Study Completion

December 1, 2019

Last Updated

May 14, 2021

Results First Posted

May 14, 2021

Record last verified: 2021-04

Data Sharing

IPD Sharing
Will not share

Locations